|
| Trial | Design | Population | Follow-up (months) | Recurrence (% idiopathic) |
|
|
Agnelli et al. [6] | RCT | PE, enrolled after 3 mos No cancer/thrombophilia screening INR 2-3 (83%) New cancer 11 patients | 3, 6, 12 after randomization, then q6 | 84.8% |
|
Agnelli et al. [7] | RCT | DVT, enrolled after 3 mos No cancer/thrombophilia screening INR 2-3 (81%) New cancer 5 patients | 3, 6, 12 after randomization, then q6 | 100% |
|
Farraj [20] | RCT | DVT and PE, enrolled after event No cancer/thrombophilia screening | q4 for 12 mos after cessation | 100% 1 event on therapy (INR = 1.8, dose missed during travel) |
|
Legnani et al. [24] | Cohort | DVT (71%), PE (29%) enrolled after 3 mos No cancer/thrombophilia screening 15 patients (2.4%) protein C, S def | 3 mos after cessation, then q6 mos | 86% |
|
Kyrle et al. [22] | Cohort | DVT (58%) and PE (42%) enrolled after 3 mos No cancer screening, had systematic thrombophilia screening HRT/OCP not excluded (175 used OCPs, 61 on HRT), females encouraged to stop after VTE New cancer in 14 patients Distal and axillary DVT included | q3 mos for first year, then q6 mos | Not specified |
|
Palareti [19] et al. * | RCT | Prox DVT (62%) and PE (38%) enrolled after 3 mos ATIII+APA screening, no cancer screen New cancer in 13 patients | q3-6 mos intervals | Not specified |
|
Palareti et al. [25] | Cohort | DVT and PE, enrolled after 3 mos No cancer/thrombophilia screening Distal DVT included D-dimer elevated in 49.3% | 3 mos after cessation, then q6 mos | Not specified |
|
Schulman et al. [21] | RCT | DVT (86%) and PE (14%), enrolled after event Prot C,S, ATIII screening, no cancer screen INR goal (2.0–2.85) | 1.5, 3, 6, 9, 12, and 24 mos | Not specified |
|
Poli et al. [23] | Cohort | DVT and PE, enrolled after 6 mos Prot C,S, ATIII, APA screening (only APA excluded), no cancer screen D-dimer elevated in 38% | Two in first year, one thereafter | 97% |
|
